BRPI0909936A2 - "composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo" - Google Patents

"composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo"

Info

Publication number
BRPI0909936A2
BRPI0909936A2 BRPI0909936A BRPI0909936A BRPI0909936A2 BR PI0909936 A2 BRPI0909936 A2 BR PI0909936A2 BR PI0909936 A BRPI0909936 A BR PI0909936A BR PI0909936 A BRPI0909936 A BR PI0909936A BR PI0909936 A2 BRPI0909936 A2 BR PI0909936A2
Authority
BR
Brazil
Prior art keywords
transdermal delivery
salt
composition
active agent
cationic active
Prior art date
Application number
BRPI0909936A
Other languages
English (en)
Inventor
Andreas Koch
Christoph Schmitz
Michael Horstmann
Mohammad Sameti
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of BRPI0909936A2 publication Critical patent/BRPI0909936A2/pt
Publication of BRPI0909936B1 publication Critical patent/BRPI0909936B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Electrochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
BRPI0909936-0A 2008-06-19 2009-06-16 Composição para liberação transdérmica BRPI0909936B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13252708P 2008-06-19 2008-06-19
US61/132,527 2008-06-19
PCT/EP2009/004316 WO2009153019A1 (en) 2008-06-19 2009-06-16 Composition for transdermal delivery of cationic active agents

Publications (2)

Publication Number Publication Date
BRPI0909936A2 true BRPI0909936A2 (pt) 2015-10-20
BRPI0909936B1 BRPI0909936B1 (pt) 2019-07-23

Family

ID=40934213

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909936-0A BRPI0909936B1 (pt) 2008-06-19 2009-06-16 Composição para liberação transdérmica

Country Status (16)

Country Link
US (2) US10881606B2 (pt)
EP (2) EP3308777A1 (pt)
JP (2) JP5620907B2 (pt)
KR (1) KR101656537B1 (pt)
CN (2) CN102046157A (pt)
AU (1) AU2009259601B2 (pt)
BR (1) BRPI0909936B1 (pt)
CA (1) CA2728975C (pt)
ES (1) ES2639576T3 (pt)
IL (1) IL210080A (pt)
MX (1) MX351262B (pt)
NZ (1) NZ590510A (pt)
PL (1) PL2285362T3 (pt)
RU (1) RU2517241C2 (pt)
WO (1) WO2009153019A1 (pt)
ZA (1) ZA201007576B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8366600B2 (en) 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
WO2015058080A1 (en) * 2013-10-17 2015-04-23 Causwave Inc. System and method for transdermal dialysis
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2017119520A1 (ko) * 2016-01-05 2017-07-13 바이오센서연구소 주식회사 역전기 투석을 이용한 마스크팩 및 그를 포함하는 키트
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN111491619B (zh) 2017-12-20 2024-06-07 Lts勒曼治疗系统股份公司 用于离子电渗透皮递送曲坦化合物的耐低温的组合物
BR112020010195A2 (pt) * 2017-12-20 2020-11-03 Lts Lohmann Therapie-Systeme Ag composição frigoestável para distribuição transdermal iontoforética de um composto de triptano
US11766558B2 (en) 2018-07-30 2023-09-26 Compass Health Brands Corp. Biomedical electrode with anti-microbial properties
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
IL291839A (en) 2019-10-01 2022-06-01 Empyrean Neuroscience Inc Genetic engineering of fungi to modulate tryptamine expression
CA3156257A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. TRANSDERMAL DELIVERY OF DRONABINOL
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
DE102020106115A1 (de) 2020-03-06 2021-09-09 Lts Lohmann Therapie-Systeme Ag Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
AU2021254855A1 (en) * 2020-04-16 2022-09-15 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of psychedelics derivatives
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20240124398A1 (en) * 2021-02-10 2024-04-18 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
JP2024514542A (ja) * 2021-03-31 2024-04-02 ライフ チェンジ， エルエルシー 催幻覚剤の治療的投与のための経皮システム、製剤、および方法
US12378194B2 (en) * 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
CN118234491A (zh) * 2021-05-26 2024-06-21 明德赛特制药公司 致幻剂-脂肪酸组合
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US222276A (en) * 1879-12-02 Improvement in combined galvanic and medicated pad
US486902A (en) * 1892-11-29 Galvanic body-battery
CA1267937A (en) * 1984-10-29 1990-04-17 Joseph Bradley Phipps Iontophoretic drug delivery
ES2082973T3 (es) * 1990-03-30 1996-04-01 Alza Corp Dispositivo para administracion iontoforetica de farmacos.
DE4014913C2 (de) * 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
US5489624A (en) * 1992-12-01 1996-02-06 Minnesota Mining And Manufacturing Company Hydrophilic pressure sensitive adhesives
CA2126487C (en) * 1993-06-23 2001-05-29 Keiichiro Okabe Iontophoresis device
US6048545A (en) * 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
CA2208332A1 (en) 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. Drug administration composition for iontophoresis
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
EP0898962A1 (en) 1997-08-28 1999-03-03 Becton, Dickinson and Company Transdermal patches and methods for inactivating skin proteases
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
JP4414517B2 (ja) * 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US6496727B1 (en) * 2000-05-31 2002-12-17 Becton, Dickinson And Company Medicament-loaded transdermal reservoir and method for its formation
DE10035891A1 (de) * 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
IT1319210B1 (it) 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6745082B2 (en) * 2001-10-22 2004-06-01 Jens Axelgaard Current-controlling electrode with adjustable contact area
JP4394444B2 (ja) * 2001-10-24 2010-01-06 パワー ペーパー リミティド 活性物質の制御された皮膚内デリバリーのためのデバイス及び方法
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
US20040242770A1 (en) * 2003-04-16 2004-12-02 Feldstein Mikhail M. Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
EA023147B1 (ru) * 2006-04-13 2016-04-29 Тева Фармасьютикалс Интернешнл Гмбх Трансдермальный пластырь для лечения мигрени
EP2040794A4 (en) * 2006-06-16 2010-10-20 Transport Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC ADMINISTRATION OF TETRACYCLIN ANTIBIOTICS
JP2010502270A (ja) * 2006-08-29 2010-01-28 アルザ・コーポレーシヨン 水和可能な貯蔵器の水和測定付きの薬品電気輸送
US8008285B2 (en) * 2007-03-09 2011-08-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis

Also Published As

Publication number Publication date
JP2011524389A (ja) 2011-09-01
ES2639576T3 (es) 2017-10-27
ZA201007576B (en) 2011-08-31
US20200113819A1 (en) 2020-04-16
JP2015007080A (ja) 2015-01-15
CA2728975A1 (en) 2009-12-23
US10881606B2 (en) 2021-01-05
IL210080A (en) 2016-03-31
IL210080A0 (en) 2011-02-28
WO2009153019A1 (en) 2009-12-23
CA2728975C (en) 2016-06-07
US20110111029A1 (en) 2011-05-12
US10881607B2 (en) 2021-01-05
CN105456181A (zh) 2016-04-06
RU2010150880A (ru) 2012-06-20
BRPI0909936B1 (pt) 2019-07-23
RU2517241C2 (ru) 2014-05-27
MX2010013853A (es) 2011-03-15
EP3308777A1 (en) 2018-04-18
AU2009259601B2 (en) 2014-09-18
JP5620907B2 (ja) 2014-11-05
MX351262B (es) 2017-10-06
KR101656537B1 (ko) 2016-09-09
KR20110028361A (ko) 2011-03-17
NZ590510A (en) 2012-08-31
EP2285362A1 (en) 2011-02-23
AU2009259601A1 (en) 2009-12-23
PL2285362T3 (pl) 2017-12-29
CN102046157A (zh) 2011-05-04
EP2285362B1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
BRPI0909936A2 (pt) "composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo"
BRPI0922584A2 (pt) composição de fluido aquoso de tratamento de poço com atividade biocida, e, método para fornecer atividade biocida em um fluido de tratamento de poço
BRPI1014390A2 (pt) composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0914405A2 (pt) "composto, composição fungicida e métodos para o controle de doenças de plantas"
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0922452A2 (pt) composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.
BRPI0910337A2 (pt) composição herbicida, uso da mesma, método para controlar vegetação indesejável e, formulação herbicida
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
BR112012022064A2 (pt) tratamento de artrite lúpica usando laquinimod
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
PT2083837E (pt) Utilização terapêutica de pelo menos uma neurotoxina botulínica no tratamento da dor induzida por, pelo menos, um agente anti-cancerígeno
BRPI0907992A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, uso do mesmo, composição farmacêutica, método de terapia em um animal de sangue quente, e, processo para preparar um composto
BRPI0720169A2 (pt) Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
BRPI1008727A2 (pt) derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
CL2012001402A1 (es) Composicion farmaceutica en suspension oftalmica acuosa de administracion topica que comprende polimero de carboxivinilo, galactomanana, borato, compuesto en nanoparticulas escasamente soluble, agentes para ajustar ph y tonicidad, conservante y quelante; metodo para tratar trastornos oftalmicos, metodo para mantener viscosidad.
BRPI1006194A2 (pt) "composição, fungicida para o controle de fungos nocivos fitopatogênicos, agente fungicida, método para o controle de fungos nocivos fitopatogênicos, semente e uso de fluopiram e metrafenona"

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF